The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

Mohty, Mohamad; Duarte, Rafael F.; Croockewit, Sandra; Hübel, Kai; Kvalheim, Gunnar; Russell, Nigel H.

doi:10.1038/leu.2010.224

Cited by 67 publications

(50 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,[36][37][38][39][40] Some of these studies advocate for early intervention based on PB CD34+ cell counts, in what has led to the emerging concept of preemptive use of plerixafor in poor mobilizers. 30,[41][42][43][44] However, clinical practice is still highly heterogeneous, and controversy in studies and practice remains about key aspects, such as the right cutoff value for intervention with plerixafor, whether the benefit from intervention would also translate to candidates with very low preapheresis PB CD34+ cell levels or the relative efficiency of remobilization strategies vs preemptive intervention in this setting.…”

Section: Introductionmentioning

confidence: 99%

Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization

Sánchez-Ortega

Querol

Encuentra

et al. 2014

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

This retrospective study presents data from 105 consecutive multiple myeloma and lymphoma patients who had PB CD34+ cell counts o 10/μL on day 4 of steady-state G-CSF mobilization for autologous hematopoietic cell transplantation. Our results confirm the capacity of plerixafor to improve mobilization outcomes in this clinical setting. In addition, they show that the effectiveness of plerixafor, compared with G-CSF only, translates to patients with very low (o 3.5/μL) circulating CD34+ cell counts: overnight CD34+ cell count expansion (5.3-vs 1.7-fold), overall CD34+ cell yield (2.29 vs 0.15 × 10 6 CD34+ cells per kg) and patients yielding ⩾ 2 × 10 6 CD34+ cells per kg (63% vs 3%). Furthermore, our data also show that preemptive plerixafor is significantly more effective and more efficient than in remobilization: CD34+ cell yield in the first apheresis (3.28 vs 2.0 × 10 6 CD34+ cells per kg) and overall (3.73 vs 2.44 × 10 6 CD34+ cells per kg), patients yielding ⩾ 2 × 10 6 CD34+ cells per kg in the first apheresis (85% vs 44%) and overall (92% vs 64%), all this requiring less days and doses of plerixafor treatment (1.08 vs 1.48). These data would advocate using plerixafor as an early preemptive intervention based on day 4 circulating CD34+ counts, including very high-risk patients with very low circulating levels.

show abstract

Section: Introductionmentioning

confidence: 99%

Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization

Sánchez-Ortega

Querol

Encuentra

et al. 2014

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plerixafor is a new agent used in combination with G-CSF in myeloma and lymphoma patients, who failed a previous mobilization attempt. 8 The action of plerixafor is based on reversible disruption of the CXCR4/SDF-1 axis by specific inhibition of the CXCR4 receptor. We hypothesized that stem-cell mobilization with plerixafor might be impaired in overweight and obese individuals, who need to mobilize and collect more CD34 þ cells in total on the basis of their higher body weight.…”

mentioning

confidence: 99%

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF

Basak

Wiktor-Jedrzejczak

Apperley

et al. 2011

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

“…7 It is very important to perform autologous transplantation in this group of diseases (myeloma, lymphomas).…”

Section: Discussionmentioning

confidence: 99%

Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

Lázár¹,

Köpeczi²,

Kakucs³

et al. 2017

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

This study presents a new method of combined growth factor mobilization with increased dose (15 μg/kg) of filgrastim and standard mono dose of plerixafor in subjects with multiple myeloma, Hodgkin or non-Hodgkin lymphoma. Efficient mobilization is a key factor in the treatment of this group of patients, because autologous transplantation can be performed in cases in which we succeed to obtain a minimally sufficient number of stem cells. Autologous stem cell transplantation is included in the current standard treatment of multiple myeloma and in the relapsed cases of lymphomas.

show abstract

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

Cited by 67 publications

References 47 publications

Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization

Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF

Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

Contact Info

Product

Resources

About